New stock news | Real Biotech's IPO prospectus is invalid
Real Biotech Limited (referred to as Real Biotech) submitted its Hong Kong Stock Exchange prospectus on November 9, 2025, which expired after 6 months on May 9, 2026, with China International Capital Corporation serving as its exclusive sponsor at the time of submission.
The IPO prospectus of True BioTech Limited (referred to as True Bio) submitted on November 9, 2025 will expire after 6 months on May 9, 2026, with CICC being its exclusive sponsor at the time of submission.
The prospectus shows that True Bio is a bio-tech company founded in 2012, with a focus on innovative research and development in the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases, as well as the development, manufacturing, and commercialization of innovative drugs.
Related Articles
Estun Automation (02715) holds 13.5 million shares of company A stock pledged by its controlling shareholder, Nanjing Pailist.
CGN Power Co., Ltd. (003816.SZ): Huizhou Unit 4 begins comprehensive construction.
On May 8th, STANCHART (02888) spent 14.634 million pounds to repurchase 777,000 shares.
Estun Automation (02715) holds 13.5 million shares of company A stock pledged by its controlling shareholder, Nanjing Pailist.
CGN Power Co., Ltd. (003816.SZ): Huizhou Unit 4 begins comprehensive construction.
On May 8th, STANCHART (02888) spent 14.634 million pounds to repurchase 777,000 shares.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
